70. Spinal stenosis Clinical trials / Disease details
Clinical trials : 95 / Drugs : 169 - (DrugBank : 61) / Drug target genes : 68 - Drug target pathways : 90
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | JPRN-JapicCTI-183866 | 02/2/2018 | 15/02/2018 | Placebo-controlled, double-blind, exploratory study of NS-304 in lumbar spinal stenosis (LSS) patients with intermittent claudication (Early Phase II study) | Placebo-controlled, double-blind, exploratory study of NS-304 in lumbar spinal stenosis (LSS) patients with intermittent claudication (Early Phase II study) | LSS | Intervention name : NS-304 INN of the intervention : Selexipag Dosage And administration of the intervention : Oral administration Control intervention name : NS-304 Placebo INN of the control intervention : - Dosage And administration of the control intervention : Oral administration | Nippon Shinyaku Co., Ltd. | NULL | complete | 40 | 79 | BOTH | 120 | Phase 2 | Japan |